Literature DB >> 3741725

Investigation of patients with abnormal response to warfarin.

D P Bentley, G Backhouse, A Hutchings, R L Haddon, B Spragg, P A Routledge.   

Abstract

In 55 patients in whom warfarin control had been satisfactory for at least 4 months, warfarin dose, plasma warfarin concentration and plasma clearance were measured. The mean dose to maintain the BCR (INR) between 2.3 and 3.3 was 5.1 +/- 2 mg day-1 (range 1.5-10 mg). Plasma warfarin concentrations and warfarin clearance were log-normally distributed with 95% confidence limits between 0.8 and 2.4 mg l-1 and 2.5 and 8.71 day-1 respectively. These confidence limits were used to construct algorithms which correctly predicted the cause of abnormal warfarin sensitivity in two patients and resistance in two further patients. These algorithms should help to identify the cause of abnormal warfarin responsiveness in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3741725      PMCID: PMC1401092          DOI: 10.1111/j.1365-2125.1986.tb02877.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  HEREDITARY TRANSMISSION OF EXCEPTIONAL RESISTANCE TO COUMARIN ANTICOAGULANT DRUGS. THE FIRST REPORTED KINDRED.

Authors:  R A O'REILLY; P M AGGELER; M S HOAG; L S LEONG; M L KROPATKIN
Journal:  N Engl J Med       Date:  1964-10-15       Impact factor: 91.245

2.  Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.

Authors:  P B Andreasen; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

3.  Interaction of warfarin and nonsystemic gastrointestinal drugs.

Authors:  D S Robinson; D M Benjamin; J J McCormack
Journal:  Clin Pharmacol Ther       Date:  1971 May-Jun       Impact factor: 6.875

4.  Dangers of amiodarone and anticoagulant treatment.

Authors:  A Rees; J J Dalal; P G Reid; A H Henderson; M J Lewis
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-30

5.  Factors affecting warfarin requirements. A prospective population study.

Authors:  P A Routledge; P H Chapman; D M Davies; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

6.  High-pressure liquid chromatographic analysis of drugs in biological fluids I. Warfarin.

Authors:  T D Bjornsson; T F Blaschke; P J Meffin
Journal:  J Pharm Sci       Date:  1977-01       Impact factor: 3.534

7.  Warfarin sodium: steady-state plasma levels and patient age.

Authors:  K Hotraphinyo; E J Triggs; B Maybloom; A Maclaine-Cross
Journal:  Clin Exp Pharmacol Physiol       Date:  1978 Mar-Apr       Impact factor: 2.557

8.  Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.

Authors:  A Yacobi; J A Udall; G Levy
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

9.  Amiodarone reduces plasma warfarin clearance in man.

Authors:  A H Watt; M R Stephens; D C Buss; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

  9 in total
  8 in total

1.  Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.

Authors:  B Vadher; D L Patterson; M Leaning
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Case studies in therapeutics: warfarin resistance and inefficacy in a man with recurrent thromboembolism, and anticoagulant-associated priapism.

Authors:  P A Routledge; H G Shetty; J P White; P Collins
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 3.  The Smith Kline & French lecture 1987. Clinical pharmacology and the art of bespoke prescribing.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 4.  Clinical utilization of the international normalized ratio (INR).

Authors:  R S Riley; D Rowe; L M Fisher
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

Review 5.  Anticoagulant therapy in special circumstances.

Authors:  T G DeLoughery
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

6.  High clearance of (S)-warfarin in a warfarin-resistant subject.

Authors:  H O Hallak; P J Wedlund; M W Modi; I H Patel; G L Lewis; B Woodruff; A A Trowbridge
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

Review 7.  Clinically important drug interactions with anticoagulants. An update.

Authors:  S Harder; P Thürmann
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 8.  Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy.

Authors:  H G Shetty; A G Fennerty; P A Routledge
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.